Tirabrutinib单药治疗复发/难治性原发性中枢神经系统淋巴瘤的疗效与安全性:PROSPECT 2期试验
PROSPECT 2期试验评估了tirabrutinib单药治疗复发/难治性原发性中枢神经系统淋巴瘤(PCNSL)的疗效与安全性。48例患者接受每日口服480mg tirabrutinib,客观缓解率(ORR)为67%,完全缓解(CR)率44%,中位缓解持续时间(DOR)9.3个月。治疗相关不良事件发生率为75%,≥3级不良事件27%,安全性总体可控。
要点
- tirabrutinib单药在R/R PCNSL中ORR达67%,CR率44%,中位TTR仅1.0个月。
- 中位DOR为9.3个月,显示快速且持久的缓解。
- 治疗相关TEAE发生率75%,≥3级27%,最常见为中性粒细胞减少和斑丘疹。
核心结论
- 每日口服tirabrutinib单药在复发/难治性PCNSL中产生快速且持久的缓解,并显示良好的安全性特征。
研究设计与样本
- 在美国开展的开放标签2期PROSPECT研究,纳入48例既往接受过≥1种大剂量甲氨蝶呤为基础治疗后进展的复发/难治性PCNSL成人患者。
- 患者接受每日一次口服tirabrutinib 480 mg,主要终点为独立评审委员会评估的客观缓解率(ORR)。
主要发现
- 中位随访11.5个月,ORR为67%(95%CI 52-80),CR率为44%(95%CI 29-59)。
- 中位DOR为9.3个月(95%CI 4.6-14.6),中位TTR为1.0个月(范围0.9-3.7)。
- 治疗相关TEAE发生于36例(75%),最常见为贫血(19%)、斑丘疹(17%)、乏力(15%)、中性粒细胞减少(15%)、淋巴细胞减少(15%)、瘙痒(15%)及其他皮疹(15%)。
- ≥3级治疗相关TEAE发生于13例(27%),最常见为中性粒细胞减少(8%)和斑丘疹(6%)。
- 1例死亡(支气管肺曲霉病)与治疗相关。
关键数值与推荐
- ORR:67%(95%CI 52-80);CR率:44%(95%CI 29-59)。
- 中位DOR:9.3个月(95%CI 4.6-14.6);中位TTR:1.0个月(范围0.9-3.7)。
- 治疗相关TEAE:75%;≥3级治疗相关TEAE:27%。
临床怎么用
- tirabrutinib单药可作为复发/难治性PCNSL的一种口服治疗选择,需关注贫血、皮疹及中性粒细胞减少等不良事件。
局限性
- 本研究为单臂2期试验,样本量48例,随访时间有限,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis, high rate of refractory or relapsed (R/R) disease, and no established standard of care for R/R PCNSL. This phase 2 study evaluated the efficacy and safety of tirabrutinib, a potent, highly selective, second-generation Bruton tyrosine kinase inhibitor, in patients with R/R PCNSL in the US. In the open-label PROSPECT study, adults with R/R PCNSL whose disease progressed on or after ≥1 high-dose methotrexate-based therapy received once-daily oral tirabrutinib 480 mg. The primary endpoint was overall response rate (ORR), and secondary endpoints included complete response (CR) rate, duration of response (DOR), and time to response (TTR), as assessed by independent review committee. Safety was assessed by frequency and severity of treatment-emergent adverse events (TEAEs). Among 48 enrolled patients, median follow-up was 11.5 months, ORR was 67% (95% confidence interval [CI], 52-80), and CR rate was 44% (95% CI, 29-59). Median DOR was 9.3 months (95% CI, 4.6-14.6), and median TTR was 1.0 month (range, 0.9-3.7). Treatment-related TEAEs occurred in 36 patients (75%), most commonly anemia (19%), maculopapular rash (17%), fatigue (15%), neutropenia (15%), lymphocytopenia (15%), pruritus (15%), and other rash (15%). Grade ≥3 treatment-related TEAEs occurred in 13 patients (27%), most commonly neutropenia (8%) and maculopapular rash (6%). One death (bronchopulmonary aspergillosis) was treatment related. In patients with R/R PCNSL, once-daily oral tirabrutinib monotherapy resulted in rapid and durable responses and demonstrated a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04947319.
引用
- Grommes C, Nayak L, Kallam A, et al. Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial. Blood. 2026. PMID: 42821736. doi:10.1182/blood.2026034926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。